ClinicalTrials.gg
CompletedNCT03402945PICS-PrevenaUpdated Feb 28, 2025

Prevention of Infections in Cardiac Surgery (PICS) Prevena Study

A Phase 4 interventional study of Prevena and Cefazolin in Surgical Site Infections, sponsored by Population Health Research Institute. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Population Health Research Institute · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies testing vancomycin in Surgical Wound Infection — 4 open to participants now, 5 under way, 1 of them phase 3. Vancomycin · Surgical Wound Infection.

Enrollment
3rd of 20
4,107 · median 329
Started
2018
with 1 other
Phase 4
9 of 20
3 open now
Registered
10th of 20
by date
Lead sponsor
1 of 20
Population Health Research Institute

Among the 20 studies testing vancomycin in Surgical Wound Infection, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 4, and was the 10th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 20 studies testing vancomycin in Surgical Wound Infection are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About vancomycin

Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing vancomycin in Surgical Wound Infection, or all of them as a file.
02

Study summary

This vanguard study will be conducted at two study sites in Canada. It is a cluster randomized trial to test a combination of two antibiotics for antibiotic prophylaxis as compared to routine prophylaxis with one single antibiotic, and to test a negative-pressure wound management system (Prevena) versus standard wound dressing to reduce chest wound infections.

Read the detailed description

Despite the routine use of antibiotics before and after cardiac surgery, infections of the chest wound remain a common life threatening complication of heart surgery that is preventable. Antibiotic prophylaxis is well accepted to be the cornerstone of prevention for these infections. The best choice of antibiotic prophylaxis in patients undergoing open heart surgery is, however, unclear. A large number of relevant pathogens are not covered by the primarily recommended antibiotic for prophylaxis, and there is a large variability in the antibiotics physicians use in practice and a lack of evidence supporting these choices. Appropriate management of the wound is probably also highly relevant in terms of infection prevention; however, there is a lack of strong evidence guiding the choice of wound management strategies as a means to reduce surgical site infection. The proposed study will test whether dual antibiotic prophylaxis is superior to single-agent prophylaxis with cefazolin, and shed light on whether or not modern negative-pressure wound management technology lower the risk of sternal surgical site infections.

03

Conditions studied

  • Surgical Site Infections

Keywords

  • negative pressure wound management system
  • open-heart surgery
  • antibiotic prophylaxis
  • surgical site infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age undergoing open-heart surgery (sternotomy, including minimally-invasive sternotomies)

Exclusion criteria

Exclusion Criteria:

  • On systemic antibiotics or with an active bacterial infection at the time of surgery
  • Patients previously enrolled in this trial
  • Patients known to be colonized with Methicillin-resistant S. aureus (MRSA)(unethical not to administer glycopeptides), beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively, or to silver precluding the use of Prevena
  • Participation in other studies that may interfere with this trial
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
4,107 participants (actual)

Study arms

  • Active comparator
    Arm 1

    cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Prevena will be applied to all diabetic and/or obese patients (BMI \>30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day

    Device: Prevena · Drug: Cefazolin

  • Active comparator
    Arm 2

    cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose. Prevena will be applied to all diabetic and/or obese patients (BMI \>30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days.

    Device: Prevena · Drug: Cefazolin · Drug: Vancomycin

  • Active comparator
    Arm 3

    cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Standard wound dressing: non-negative wound dressing as standard of care at the study site.

    Drug: Cefazolin · Other: standard wound dressing

  • Active comparator
    Arm 4

    cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose. Standard wound dressing: non-negative wound dressing as standard of care at the study site.

    Drug: Cefazolin · Drug: Vancomycin · Other: standard wound dressing

Interventions

  • DevicePrevena

    Negative-Pressure Wound Management System

  • antibiotic

  • antibiotic

    Also known as: Vancocin

  • Otherstandard wound dressing

    Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.

06

What researchers measure

Primary outcomes

  1. Adherence to the wound management system

    goal is \>90%

    Time frame: Prevena or standard wound dressing applied after surgery as per protocol, assessed up to 90 days after surgery

  2. Adherence to the antibiotic regimen

    goal is \>90%

    Time frame: Cefazolin: within an hour of surgery; one intra-operative dose at 4 hours after the first dose or upon wound closure (whatever comes first); two post-operative doses q8h. Vancomycin: initially intravenously; second dose 12 hrs after the first dose.

  3. Loss of follow-up

    goal is \<10%

    Time frame: up to 90 days after surgery

Secondary outcomes

  1. Deep incisional and organ/space sternal-surgical site infection (s-SSI)

    using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions

    Time frame: up to 90 days after surgery

  2. Wound dehiscence

    using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions

    Time frame: up to 90 days after surgery

  3. C. difficile infection

    laboratory confirmed

    Time frame: up to 90 days after surgery

  4. Mortality in patients with an active infection

    using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions

    Time frame: up to 90 days after surgery

  5. ICU (Intensive Care Unit) and hospital stay

    length

    Time frame: Length of ICU - from date of surgery to initial ICU discharge date, assessed up to 90 days after surgery. Hospital Stay - date of surgery to date of hospital discharge, assessed up to 90 days after surgery.

  6. Pain on day 7

    Visual analog scale (VAS)

    Time frame: Pain at Day 7 (+/- 1 day)

  7. Acute kidney injury

    Based on serum creatinine, following Acute Kidney Injury Network definition

    Time frame: within 7 days of surgery

07

Study locations

2 sites
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
  • London Health Sciences Centre & Lawson Health Research Institute
    London, Ontario N6A 5A5, Canada
08

References and documents

Publications

  • Connolly SJ, Philippon F, Longtin Y, Casanova A, Birnie DH, Exner DV, Dorian P, Prakash R, Alings M, Krahn AD. Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). Can J Cardiol. 2013 Jun;29(6):652-8. doi: 10.1016/j.cjca.2013.01.020. Erratum In: Can J Cardiol. 2013 Jul;29(7):889. PubMed 23702356 ↗
  • Mertz D, Whitlock R, Kokoszka AY, Smith SW, Carignan A, Rehan M, Jaffer IH, Alsagheir A, Loeb M. Routine Surveillance Versus Independent Assessment by an Outcome Adjudication Committee in Assessing Patients for Sternal Surgical Site Infections After Cardiac Surgery. Infect Control Hosp Epidemiol. 2016 May;37(5):600-2. doi: 10.1017/ice.2015.347. Epub 2016 Jan 19. PubMed 26782707 ↗
  • Filsoufi F, Castillo JG, Rahmanian PB, Broumand SR, Silvay G, Carpentier A, Adams DH. Epidemiology of deep sternal wound infection in cardiac surgery. J Cardiothorac Vasc Anesth. 2009 Aug;23(4):488-94. doi: 10.1053/j.jvca.2009.02.007. Epub 2009 Apr 19. PubMed 19376733 ↗
  • Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. Ann Thorac Surg. 2006 Jan;81(1):397-404. doi: 10.1016/j.athoracsur.2005.06.034. No abstract available. PubMed 16368422 ↗
  • Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L, Paul M. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. J Antimicrob Chemother. 2012 Mar;67(3):541-50. doi: 10.1093/jac/dkr470. Epub 2011 Nov 13. PubMed 22083832 ↗
  • Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. Ann Surg. 2011 Jul;254(1):48-54. doi: 10.1097/SLA.0b013e318214b7e4. PubMed 21412147 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Apr 2023, 61 months.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's 61 months is above that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 18, 2018
StartActual
Mar 5, 2018
Primary completionActual
Apr 27, 2023
CompletionActual
Oct 17, 2024
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03402945
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Mar 5, 2018
Primary completion
Apr 27, 2023
Completion
Oct 17, 2024
Last update
Feb 28, 2025

Study contacts

Dominik Mertz, MD,MSc
principal investigator · Juravinski Hospital and Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vancomycin

Start the discussion